Alterations of the retinoic acid receptor (RAR)a locus are found in 100% of acute promyelocytic leukemia patients, where chromosomal translocations generate the promyelocytic leukemia (PML)-RARa chimeric protein. Here, we have investigated the biological properties of the other RAR isoforms (RARb and RARc), through the generation and characterization of artificial PML-RAR'x' fusion proteins. Surprisingly, we found that all of the RAR isoforms share an identical oncogenic potential in vitro, thus implying that the selection of the RARa locus in leukemia patients must occur -rather than through functional differences among the various RAR isoforms-as the consequence of the nuclear architecture of the different RAR loci.
Introduction
Acute promyelocytic leukemia (APL) is caused by chromosomal translocations, which involve invariably the a isoform of the retinoic acid receptor (RAR), and in 490% of the cases the promyelocytic leukemia (PML) locus, to yield the oncogenic PML-RARa fusion protein.
1 PML-RARa behaves as an altered RARa, and represses transcription of RA target genes more efficiently than the wild-type receptor in the absence of retinoic acid, owing to altered recruitment of chromatin modifiers. 2, 3 The altered functioning of PML-RARa results in the block of hematopoietic differentiation, and in the acquisition of enhanced self-renewal properties that are essential features of the leukemic blasts. 4 RARa is not the unique member of the RAR family, which includes two other isoforms (RARb and RARg) encoded by separate loci. 5 The receptors share a high sequence homology (Figure 1a ), but show distinct transcriptional properties and expression patterns, suggesting similar but not necessarily overlapping functions. 6 The striking, exclusive selection of the RARa locus in APL may therefore imply that the a isoform is uniquely poised to acquire oncogenic properties upon fusion. Alternatively, topological constrains may play a decisive role in selecting for this locus, as chromosomes 15 and 17 (where the loci for RARa and PML are located) are non-randomly juxtaposed within the nucleus of hematopoietic cells, in contrast to chromosomes 3 and 12, where RARb and RARg are located. 7 We decided to take an experimental approach to start to address this question, and studied the transcriptional and biological properties of chimeras where PML was fused to the regions of RARb and RARg corresponding to the RARa region found in the naturally occurring APL, to generate the PML-RARb and PML-RARg fusion proteins (Figure 1a ).
Materials and methods

Expression vectors
RARa, RARb, RARg and PML-RARa expression vectors have been described. 8 The artificial chimeric protein PML/RARb and PML/RARg were constructed by polymerase chain reaction (PCR)-mediated amplification of the appropriate regions of PML and RARb/RARg, and then cloning in the PINCO and pcDNA3 expression vectors. All of the constructs have been verified by complete DNA sequencing.
Transient transfections
Transient transfections of 293T cells were performed as described previously. 9 Analysis of differentiation and proliferative potential of murine hematopoietic progenitors Lineage minus (linÀ) murine hematopoietic progenitors were purified and transduced with retroviral vectors encoding for PML-RARa, PML-RARb and PML-RARg. Transduced cells were sorted by cytofluorimetry (using the co-expressed GFP (green fluorescent protein) as a selection marker), and then either: (a) plated in semisolid, methylcellulose medium contaning a cocktail of cytokines to induce myeloid differentiation (interleukin-3 (IL-3) , IL-6, SCF, G-CSF and GM-CSF); or (b) serially plated in methylcellulose-based medium containing IL-3, IL-6 and SCF as described previously. 4 
Analysis of RNA and protein expression
Whole-cell extracts were prepared from 293 T or linÀ cells as described. 8 Immunoblot analysis was performed using anti-PML antibodies (sc -5621 from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Total RNA was purified from linÀ cells, reverse transcribed and analyzed by quantitative PCR using the following primers for human PML: PML for 5 0 -GTA AAC GGC CAC AAG TTC AGC-3 0 ; PMLrev 5 0 -GCA GAT GAA CTT CAG GGT CAG C-3 0 . b-Actin was used for normalization.
Results and discussion
At first, we analyzed the transcriptional properties of PML-RAR chimeric proteins, as opposed to the natural RAR isoforms. 293 T cells were transiently transfected with the natural RARb2 reporter construct, which has been routinely used to study the activity of RARs and of PML-RARa. 10 As previously shown, RARa is a stronger repressor than RARb, probably for its higher capacity to associate with transcriptional co-repressors (Figure 1c) . 11, 12 RARg behaves similar to RARa (Figure 1c ). Interestingly, PML-RARa, PML-RARb and PML-RARg (which were expressed at comparable levels upon transfection: see Figure 1b ) showed an almost identical transcriptional repressive activity on this promoter, and were stronger repressors than wild-type RARs (Figure 1e ). Retinoic acid (RA) reverts the transcriptional repression by RARs, and results in a weak, but reproducible activation of the promoter, which was less evident in cells expressing RARg (Figure 1d ). RA treatment results in downregulation of the protein levels of all PML-RAR chimeric proteins, owing to proteasome degradation (Figure 1b) . 13 As described previously, in the presence of RA, PML-RARa behaved as a stronger activator compared to RARa . PML-RARb behaved similarly to PML-RARa, whereas PML-RARg (in parallel to the wild-type RARg) showed a weaker response to RA treatment (Figure 1f) . Overall, these results suggest that the transcriptional activities of PML-RARb and PML-RARg are not significantly different than those observed in PML-RARa. We therefore investigated whether PML-RARb and PML-RARg could mimic the biological effects observed upon expression of PML-RARa in murine hematopoietic progenitors (linÀ). In this system, PML-RARa induces an APL-like leukemia, which responds to pharmacological doses of RA, as observed in human patients. 4 We expressed all of the PML-RAR chimeras in linÀ cells: the expression was comparable for all constructs, both at the RNA and protein levels (Figure 2a, b) . Interestingly, PML-RARb and PML-RARg can reproduce two key biological effects mediated by PML-RARa: (a) the capacity to block myeloid differentiation of linÀ cells exposed to a cocktail of pro-differentiating cytokines, as measured by the decrease in cells expressing Taken together, these results indicate that there is not a functional selection of RARa as the most appropriate oncogenic fusion partner in APL. RARb and RARg, when fused to PML, yield chimeric proteins that strikingly resemble the properties of PML-RARa.
It is perhaps surprising that we observe uniform results in our transcriptional and biological assays using different RAR fusion proteins, as others have shown different properties of RARa, as opposed to the RARb and RARg isoforms. 11, 12 RARb has been proposed as a tumor suppressor gene, at least for some forms of tumors.
14 The differences observed among RARs may be celltype specific, or the oligomerization of RARs owing to the PML moiety tends to abate biochemical properties uniquely shown by specific isoforms.
From an analysis of the expression data, RARa is by far the most abundantly expressed RAR isoform in both human CD34 þ and murine linÀ hematopoietic progenitors, RARb and RARg being essentially undetectable (our unpublished results). During DNA synthesis, the active transcriptional regions of PML and RARa are presumably replicated together during early S phase, and illegitimate recombination may occur. The chromatin architecture of the RARa locus (being more open than the silent RARb and RARg loci) may therefore be uniquely poised to rearrangements among the RAR isoforms, favored by the close vicinity of the 15 and 17 chromosomes in hematopoietic cells. 7, 15 In the case of APL, global and local genomic topologies may therefore affect the insurgence of oncogenic rearrangements in a dominant way over the biological features shown by a subset of genes that have identical oncogenic potential. Chimeric PML-RAR'x' oncoproteins A Marinelli et al
